Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560321 | 0.96 | FKBP1A (0.57) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27462940 | 0.92 | SMN1; SMN2 (0.55) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27445286 | 0.92 | SMN1; SMN2 (0.55) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31551949 | 0.85 | NPSR1 (0.59) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30845587 | 0.85 | PREP (0.53) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13994810 | 0.84 | PREP (0.57) | PREPNPSR1ACE2ALDH1A1TSHR | |
| SCHEMBL9977516 | 0.84 | SMN1; SMN2 (0.53) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14404742 | 0.84 | SMN1; SMN2 (0.53) | PREPNPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL791439 | 0.84 | PREP (0.57) | PREPNPSR1ACE2ALDH1A1TSHR | |
| SCHEMBL31323545 | 0.84 | NPSR1 (0.51) | PREPNPSR1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960383-B1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| EP-1658066-B9 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1658066-B1 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2009-09-30 | — | — | EP | disclosed |
| EP-1997489-A1 | Adamantylglycine derivatives as inhibitors of dipeptidyl peptidase IV for the treatment of diabetes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1960383-A1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7388095-B2 | 5-substituted indole-2-carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007063000-A1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123525-A1 | 5-Substituted indole-2-carboxamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
| US-6995183-B2 | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050239839-A1 | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods | HAMANN LAWRENCE G | 2005-10-27 | — | — | US | disclosed |
| US-20050228021-A1 | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods | HAMANN LAWRENCE G | 2005-10-13 | — | — | US | disclosed |
| US-20050038020-A1 | such as (S)-[1-(3-hydroxyadamantan-1-yl)-2-oxo-2-pyrrolidin-1-ylethyl]amine; for treatment of diabetes | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-17 | — | — | US | disclosed |
| US-4234484-A | FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038020-A1 | such as (S)-[1-(3-hydroxyadamantan-1-yl)-2-oxo-2-pyrrolidin-1-ylethyl]amine; for treatment of diabetes | ADCY2, ADCY1, GLP1R | PREP 2366/4885NPSR1 1797/4885SMN1; SMN2 1713/4885 |
| US-20050239839-A1 | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP3, DPP7 | PREP 19/4885NPSR1 1424/4885SMN1; SMN2 1928/4885 |
| US-20070123525-A1 | 5-Substituted indole-2-carboxamide derivatives | HRH4, HRH3, HCAR2 | PREP 2861/4885NPSR1 32/4885SMN1; SMN2 3694/4885 |
| US-20050228021-A1 | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP3, DPP7 | PREP 19/4885NPSR1 1424/4885SMN1; SMN2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.